Ozmosi | AX-0811 Drug Profile
Drug Profile
Using advanced filters...

AX-0811

Alternative Names: AX-0811, AX0811, AX 0811
Clinical Status: Active
Latest Update: 2026-10-29
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.benzinga.com/pressreleases/26/10/g62650229/proqr-present-clinical-and-preclinical-progress-ax-0810-and-ax-0811-upcoming-conferences)

Mechanisms of Action: NTCP Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: ProQR
Company Location: Europe
Company Founding Year: 2012
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AX-0811

Countries in Clinic: Belgium

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Expected - ProQR announced they will present P0 Biliary Atresia|Bile Duct Diseases results in 4Q26 for AX-0811
  • Clinical Outcomes Expected - ProQR announced they will present P1 Healthy Volunteers results in 1Q27 for AX-0811
  • Clinical Outcomes Expected - ProQR announced they will present P2 Biliary Atresia results in 3Q28 for AX-0811

Highest Development Phases

Phase 1: Healthy Volunteers

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2026-526764-21-00

PQ-0811-101

P1

Not yet recruiting

Healthy Volunteers

2027-04-29

Recent News Events

Date

Type

Title